A little help from residual β cells has long-lasting clinical benefits

Lam, Anna, Dayan, Colin ORCID: https://orcid.org/0000-0002-6557-3462 and Herold, Kevan C. 2021. A little help from residual β cells has long-lasting clinical benefits. Journal of Clinical Investigation 131 (3) , e143683. 10.1172/JCI143683

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (376kB) | Preview

Abstract

Following type 1 diabetes (T1D) diagnosis, declining C-peptide levels reflect deteriorating β cell function. However, the precise C-peptide levels that indicate protection from severe hypoglycemia remain unknown. In this issue of the JCI, Gubitosi-Klug et al. studied participants from the landmark and ongoing Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and Complications (EDIC) study that had long-standing (about 35 years) T1D. The authors correlated severe hypoglycemia and other disease outcomes with residual C-peptide levels. While C-peptide secretion failed to associate with hemoglobin A1c (HbA1c) or microvascular complications, C-peptide levels greater than 0.03 nmol/L were linked with fewer episodes of severe hypoglycemia. These findings suggest that efforts to preserve finite β cell function early in T1D can have meaningful, long-standing health benefits for patients.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Publisher:	American Society for Clinical Investigation
ISSN:	0021-9738
Date of First Compliant Deposit:	16 June 2022
Date of Acceptance:	1 February 2021
Last Modified:	21 May 2023 22:05
URI:	https://orca.cardiff.ac.uk/id/eprint/150573

Citation Data

Cited 2 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item